Castration Resistant Prostate Cancer Research Of Individualized Drug Therapy

Objective:To study the individualized chemotherapy drug castration resistant prostate cancer(CRPC) clinical effect.Methods:Prospective, randomized, controlled method, will in February 2013 to December2014, shanxi medical university first hospital uropoiesis surgical department of 41 patients with CRPC were randomly divided into 2 groups.Treatment group detection TUBB3, ERCC1 gene m RNA and MDR1 gene polymorphism, according to the results of the choice of targeted chemotherapy regimens, individualized selection of common three kinds of chemotherapy drugs, including his dorsey, mitoxantrone,cisplatin;More than the control group only with west he match treatment;Change from two groups patients serum TPSA, tumor lesions, bone scan, the patient pain score metrics such as comparison, every three weeks for a cycle, continuous assessment after treatment for 6 cycles. cisplatin;More than the control group only with west he match treatment;Change from two groups patients serum TPSA, tumor lesions, bone scan, the patient pain score metrics such as comparison, every three weeks for a cycle,continuous.Results:(1) after treatment, the treatment group serum TPSA value was 30.9 ± 5.43,the control group, serum TPSA value was 39.1 ± 7.7 curative effect comparison between;(2) after treatment, the treatment group pain score value of 5.5 ± 0.94,control pain score value of 6.4±1.27, curative effect comparison between;(3) after treatment, the treatment group metastatic lesions significantly reduced bone scan,decrease rate compared with;(4) after treatment, the treatment group significantly.Conclusions:Individualized chemotherapy for patients with CRPC targeted strong, good curative effect, can make the patients survival benefit, has clinical value.